Autopsy report · NCT07267130
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects
Cause of deathFunding or business
“This study shall be terminated as a result of strategic adjustments to the company-sponsored research and development of TQC3302 Inhalation Spray.”
Life of this trial
- Ran for about 9 months before it stopped.
- 33 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
- Sponsor type
- Industry
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- TQC3302 inhalation spray; TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation; Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray; Budesonide Powder for Inhalation+ TQC3302 inhalation spray+ Tiotropium bromide and olodaterol hydrochloride inhalation spray; TQC3302 inhalation spray
- Participants
- 33
- Sites
- 1
- Countries
- China
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.